TRISCEND II: Transcatheter tricuspid valve replacement in patients with severe TR

Reported from TCT 2023

Mirvat Alasnag interviews Susheel K. Kodali about the results of the TRISCEND II trial which he presented during the TCT Congress 2023 in San Francisco.

Data from the first 150 patients revealed that transcatheter valve replacement effectively improved tricuspid regurgitation and patient symptoms with low adverse events at 30 days, offering a valuable treatment option for severe tricuspid regurgitation, particularly in elderly individuals unsuitable for surgery.